Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ureteral Stent, Ureteral Stent · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Percuflex Plus Ureteral Stent |
| 2 | EXPERIMENTAL | TRIUMPH stent (triclosan-eluting stent) |
| Name | Type | Description |
|---|---|---|
| Ureteral Stent | DEVICE | triclosan-eluting ureteral stent |
Inclusion Criteria: * Patients who undergo ureteroscopy for any reason and require a ureteral stent post-operatively as determined by the surgeon (e.g. renal obstruction, ureteral edema, ureteral perforation, large stone fragments to pass, following ureteral dilation, ureteral trauma, solitary kidn...
Ureteral Stent is an investigational device being studied for use in patients with renal calculi, or kidney stones. It is designed to be placed in the ureter to help maintain drainage and potentially reduce complications associated with stone disease. The device is currently in Phase 2 clinical development.
Ureteral Stent is being developed by Boston Scientific Corporation, a medical device company traded on the New York Stock Exchange under the ticker symbol BSX. The company is conducting clinical research to evaluate the safety and effectiveness of this investigational ureteral stent in patients with renal calculi.
Ureteral Stent is in Phase 2 clinical development. It is an investigational device and has not yet been approved by regulatory authorities. One Phase 2 clinical trial has been completed, and the device remains under study for its intended use in patients with renal calculi.
Ureteral Stent has one completed clinical trial registered under NCT00250406, titled "Assessment of Drug-eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation." This Phase 2 study enrolled 20 participants in Canada and evaluated the device in patients with renal calculi and ureteral obstruction.
Ureteral Stent is an investigational device that is being evaluated as a drug-eluting ureteral stent. The clinical trial NCT00250406 specifically assesses the drug-eluting properties of the stent, focusing on bacterial adherence and biofilm formation. This indicates the stent is designed to release a drug to potentially reduce infection-related complications.